# A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Source: https://onco.cc/trials/nct06907043/  
OnCo record `nct06907043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06907043 as recruiting, last updated 2025-08-19. Enrolment is 130 planned participants, an estimate. Interventions: EIK1004-001 (IMP1707-001). Primary measures include Number of Participants who experience a Dose-Limiting Toxicity (DLT); Number of participants with adverse events, treatment emergent adverse events or serious adverse events. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06907043
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors
- Sponsor: Eikon Therapeutics

## Sources

- ClinicalTrials.gov NCT06907043: https://clinicaltrials.gov/study/NCT06907043

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [EIK1004](https://onco.cc/drugs/eik1004/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06907043.json